Dec 9, 2024 · Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. Includes …

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive …

Nov 26, 2025 · So, nadofaragene firadenovec, which is also known as Adstiladrin, is one such gene therapy for bladder cancer that no longer responds to PCG treatment. And importantly, gene therapy …

Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients …

Apr 8, 2024 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin …

Clinical overview Indication: ADSTILADRIN® (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk …

Nov 12, 2025 · Simple Summary Some bladder cancers do not respond to the usual Bacillus Calmette-Guérin (BCG) treatment, leaving patients with few options, often requiring complete bladder removal. …

The National Comprehensive Cancer Network (NCCN) bladder cancer clinical guidelines (version 1.2025 – March 25, 2025) recommend Adstiladrin for the treatment of BCG-unresponsive, high-risk …

Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells. …

Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy designed for high-risk BCG-unresponsive NMIBC. It represents a groundbreaking advancement in the treatment …